[Hemophagocytic syndrome: diagnostic problems].
Hemophagocytic syndrome (HS) is a rare but life-threatening disease caused by inappropriate activation of T-lymphocytes and histiocytes, hipercytokinemia and hemophagocytosis. The most common symptoms are fever, hepatosplenomegaly, unspecific neurological abnormalities, pancytopenia, coagulopathy, hiperferritinemia and lipid abnormalities. HS is classified into two forms: primary, inherited (Familial Hamophagocytic Lymphohistiocytosis--FHL) and secondary (associated with infection, malignancy, autoimmune disease). In spite of the fact that diagnostic guidelines are available it often remains unrecognised. Prognosis of HS depends on the form of disease and in case of secondary HS on the underlying disease. Development of the treatment protocols (HLH-94, HLH-2004) which combine immunochemiotherapy with hematopoietic stem cell transplantation has strongly improved prognosis in HS especially in the primary form. Three-year overall survival for children with HS is now over 50%. Early diagnosis and appropriate therapy is crucial for effectiveness of the treatment. Popularisation of the knowledge about the syndrome, diagnostic guidelines and treatment protocols can contribute to more frequent appropriate recognition of HS and to improvement of the treatment results.
Czogała
Małgorzata
M
Studenckie Koło Naukowe przy Klinice Onkologii i Hematologii Dzieciecej Polsko-Amerykańskiego Instytutu Pediatrii Collegium Medicum Uniwersytetu Jagiellońskiego w Krakowie.
Czogała
Wojciech
W
Balwierz
Walentyna
W
D002648:Child; D003937:Diagnosis, Differential; D015620:Histiocytic Disorders, Malignant / Q000175:diagnosis* / Q000453:epidemiology / Q000235:genetics / Q000276:immunology; D015616:Histiocytosis, Non-Langerhans-Cell / Q000175:diagnosis* / Q000453:epidemiology / Q000235:genetics / Q000276:immunology; D006801:Humans; D051359:Lymphohistiocytosis, Hemophagocytic / Q000175:diagnosis*; D013577:Syndrome; D013601:T-Lymphocytes / Q000276:immunology / Q000473:pathology